CH660688B - - Google Patents

Info

Publication number
CH660688B
CH660688B CH170584A CH170584A CH660688B CH 660688 B CH660688 B CH 660688B CH 170584 A CH170584 A CH 170584A CH 170584 A CH170584 A CH 170584A CH 660688 B CH660688 B CH 660688B
Authority
CH
Switzerland
Prior art keywords
theophylline
total
hours
released
measurement
Prior art date
Application number
CH170584A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CH660688B publication Critical patent/CH660688B/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH170584A 1983-04-06 1984-04-04 CH660688B (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE789/83A IE55745B1 (en) 1983-04-06 1983-04-06 Sustained absorption pharmaceutical composition

Publications (1)

Publication Number Publication Date
CH660688B true CH660688B (fr) 1987-06-15

Family

ID=11018164

Family Applications (1)

Application Number Title Priority Date Filing Date
CH170584A CH660688B (fr) 1983-04-06 1984-04-04

Country Status (9)

Country Link
US (2) US4663150A (fr)
EP (1) EP0122077B1 (fr)
JP (1) JPS59219219A (fr)
AT (1) ATE53176T1 (fr)
BE (1) BE899293A (fr)
CH (1) CH660688B (fr)
DE (1) DE3482374D1 (fr)
IE (1) IE55745B1 (fr)
PH (1) PH18904A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
IE58246B1 (en) * 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
GB2170104A (en) * 1985-01-30 1986-07-30 Warner Lambert Co Coated pharmaceutical dosage forms
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids
IL84599A0 (en) * 1986-12-09 1988-04-29 Byk Gulden Lomberg Chem Fab Pharmaceutical composition containing urapidil and process for the preparation thereof
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
CA1323833C (fr) * 1987-04-28 1993-11-02 Yatindra M. Joshi Compositions pharmaceutiques sous forme de granules et methode de fabrication
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
ATE241987T1 (de) * 1987-10-16 2003-06-15 Elan Corp Plc Diltiazem-zusammensetzungen mit kontrollierter wirkstoffabsorption
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE3929864A1 (de) * 1989-09-08 1991-03-14 Nordmark Arzneimittel Gmbh Verfahren zur herstellung von theophyllin-pellets
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
EP0585355B1 (fr) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Composition multicouche a liberation regulee
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20060068017A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6168801B1 (en) * 1998-09-09 2001-01-02 Cardiac Pacemakers, Inc. Controlled release drug delivery
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
BR0314036A (pt) * 2002-09-04 2005-07-12 Ranbaxy Lab Ltd Apresentações farmacêuticas com mascaramento de sabor e processo para sua preparação
GB0227948D0 (en) * 2002-11-29 2003-01-08 Cipla Ltd Pharmaceutical combinations comprising b-2 adrenoreceptor agonists and xanthines
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
DE10353196A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
WO2006102964A2 (fr) * 2005-03-29 2006-10-05 Evonik Röhm Gmbh Forme pharmaceutique multiparticulaire constituee de pellets renfermant une substance ayant un effet modulaire sur la liberation de l'ingredient actif
EP1743638A1 (fr) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Formulations pharmaceutiques des derivés de la pyrazoline
AU2006269944A1 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
RU2428176C2 (ru) * 2006-01-27 2011-09-10 Юранд, Инк. Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
BRPI0621996B8 (pt) * 2006-08-18 2022-07-05 Evonik Roehm Gmbh preparação farmacêutica compreendendo um núcleo com um ingrediente ativo e com um ácido orgânico e/ou com o sal de um ácido orgânico, e um revestimento que envolve o núcleo e que compreende um ou mais copolímeros de (met)acrilato, e seu uso.
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US8992898B2 (en) 2010-04-17 2015-03-31 Shannon Elizabeth Klingman Antiperspirants and deodorants
CA2902911C (fr) 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
RS61368B1 (sr) * 2018-09-27 2021-02-26 Inibsa Ginecologia S A Postupak za pripremu višejediničnog oralnog doznog oblika sa modifikovanim oslobađanjem doksilamin sukcinata i piridoksin hidrohlorida
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853420A (en) * 1956-01-25 1958-09-23 Lowey Hans Ethyl cellulose coatings for shaped medicinal preparations
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
NL270408A (fr) * 1960-10-20
NL297088A (fr) * 1961-01-31
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
NL297631A (fr) * 1963-06-03
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
US3400185A (en) * 1965-04-08 1968-09-03 Bristol Myers Co Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
US3906087A (en) * 1973-09-10 1975-09-16 Union Corp Sustained release of methantheline
US4085214A (en) * 1976-10-18 1978-04-18 Interx Research Corporation Stable pro-drug forms of theophylline
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS56122311A (en) * 1980-02-29 1981-09-25 Eisai Co Ltd Lasting theophylline pharmaceutical composition
NZ196349A (en) * 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
JPS58501128A (ja) * 1981-07-15 1983-07-14 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 徐放性テオフイリン
IT1153487B (it) * 1982-04-15 1987-01-14 Prophin Lab Spa Prodotti farmaceutici in forma-ritardo e procedimento per ottenerli
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules

Also Published As

Publication number Publication date
EP0122077B1 (fr) 1990-05-30
US4663150A (en) 1987-05-05
IE55745B1 (en) 1991-01-02
EP0122077A2 (fr) 1984-10-17
BE899293A (fr) 1984-07-16
JPH0466207B2 (fr) 1992-10-22
ATE53176T1 (de) 1990-06-15
EP0122077A3 (en) 1985-09-11
DE3482374D1 (de) 1990-07-05
US4820521A (en) 1989-04-11
PH18904A (en) 1985-10-30
JPS59219219A (ja) 1984-12-10

Similar Documents

Publication Publication Date Title
CH660688B (fr)
IE833057L (en) Controlled absorption formulation
DE3478396D1 (en) Controlled absorption pharmaceutical formulation
US4767628B1 (fr)
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
AU2377588A (en) Controlled absorption diltiazem formulations
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ZA884622B (en) Pharmaceutical compositions in the form of pellets with enzymatically controlled release of the pharmaceutical,substance
ES8601756A1 (es) Metodo de fabricar una estructura compuesta coherente.
ATE72118T1 (de) Pharmazeutische zusammensetzung und verfahren zu ihrer herstellung.
JPS6440423A (en) Patch for mucosa in oral cavity
IL66742A (en) Derivatives of 2,2-dimethyl-3-haloalkenyl-cyclopropane carboxylic acid esters with fluorinated-3-trifluoromethoxy benzyl alcohols and 5-(2-fluoro-1,3-benzodioxole)methanols,their preparation and their use as pesticides
ZA825702B (en) Novel phenoxyphenylamino acid derivatives, the production thereof, composition containing the and use thereof
ES514937A0 (es) "procedimiento de preparar derivados del acido sulfamico y similares".
JPS57212186A (en) Clavulanic acid derivative, manufacture and use
NO892692L (no) Fremgangsmaate for fremstilling av 5-fluornikotinsyre-derivater og salter derav eller 2-(5-fluornikotinoyl) - eddiksyrederivater.
ATE98679T1 (de) Herstellung des hblv-virus in der hsb-2 zelllinie.
JPS57212187A (en) Clavulanic acid derivative, manufacture and use